Nan Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nan Fang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Jue Fan
Singleron Biotechnologies, Nanjing, Jiangsu, China
2 shared publications - Margarete Odenthal
Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
2 shared publications Anwen Xiong
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publication- Axel Maximilian Hillmer
Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
1 shared publication - Caicun Zhou
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
1 shared publication - Chenghui Zhou
Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, 50937 Cologne, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
CellFM: a large-scale foundation model pre-trained on transcriptomics of 100 million human cells
Single-cell sequencing provides transcriptomic profiling at single-cell resolution, uncovering cellular heterogeneity with unprecedented precision. Yet, current single cell data analysis suffers from the inherent data noises, batch effects, and sparsity, highlighting the requirement of a unified model to represent cellular states. To circumvent this problem, many recent efforts focus on training single-cell foundation models based on large datasets. However, current human foundation models are still limited by the sizes of training data and model parameters. Here, we have collected a diverse dataset of 100 million human cells, on which we train a single-cell foundation model (CellFM) containing 800 million parameters. To balance efficiency and performance, the model is trained through a modified RetNet framework on the MindSpore. Extensive experiments have shown that CellFM outperforms existing models in cell annotation, perturbation prediction, gene function prediction, and gene-gene relationship capturing.
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Top Cited PapersOpen AccessCellFM: a large-scale foundation model pre-trained on transcriptomics of 100 million human cells
Single-cell sequencing provides transcriptomic profiling at single-cell resolution, uncovering cellular heterogeneity with unprecedented precision. Yet, current single cell data analysis suffers from the inherent data noises, batch effects, and sparsity, highlighting the requirement of a unified model to represent cellular states. To circumvent this problem, many recent efforts focus on training single-cell foundation models based on large datasets. However, current human foundation models are still limited by the sizes of training data and model parameters. Here, we have collected a diverse dataset of 100 million human cells, on which we train a single-cell foundation model (CellFM) containing 800 million parameters. To balance efficiency and performance, the model is trained through a modified RetNet framework on the MindSpore. Extensive experiments have shown that CellFM outperforms existing models in cell annotation, perturbation prediction, gene function prediction, and gene-gene relationship capturing.
- Top Cited PapersOpen Access
- 5 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment. To map the cell type-specific transcriptome landscape of cancer cells and their tumor microenvironment in advanced non-small cell lung cancer (NSCLC), we analyze 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and present the large scale, single cell resolution profiles of advanced NSCLCs. In addition to cell types described in previous single cell studies of early stage lung cancer, we are able to identify rare cell types in tumors such as follicular dendritic cells and T helper 17 cells. Tumors from different patients display large heterogeneity in cellular composition, chromosomal structure, developmental trajectory, intercellular signaling network and phenotype dominance. Our study also reveals a correlation of tumor heterogeneity with tumor associated neutrophils, which might help to shed light on their function in NSCLC.
- 5 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-11
Top Cited PapersOpen AccessSingle-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment. To map the cell type-specific transcriptome landscape of cancer cells and their tumor microenvironment in advanced non-small cell lung cancer (NSCLC), we analyze 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and present the large scale, single cell resolution profiles of advanced NSCLCs. In addition to cell types described in previous single cell studies of early stage lung cancer, we are able to identify rare cell types in tumors such as follicular dendritic cells and T helper 17 cells. Tumors from different patients display large heterogeneity in cellular composition, chromosomal structure, developmental trajectory, intercellular signaling network and phenotype dominance. Our study also reveals a correlation of tumor heterogeneity with tumor associated neutrophils, which might help to shed light on their function in NSCLC.
- 20 September 2020
- Published by Springer Nature
- Vol. 1255, 109-121
Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment
Cancer is one of the leading causes of death worldwide and well known for its complexity. Cancer cells within the same tumor or from different tumors are highly heterogeneous. Furthermore, stromal and immune cells within tumor microenvironment interact with cancer cells to play important roles in how tumors progress and respond to different treatments. Recent advances in single cell technologies, especially massively parallel single cell sequencing, have made it possible to analyze cancer cells and cells in its tumor microenvironment in parallel with unprecedented high resolution. In this chapter, we will review recent developments in single cell sequencing technologies and their applications in cancer research. We will also explain how insights generated from single cell sequencing can be used to develop novel diagnostic and therapeutic approaches to conquer cancer.
- 20 September 2020
- Published by Springer Nature
- Vol. 1255, 109-121
Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment
Cancer is one of the leading causes of death worldwide and well known for its complexity. Cancer cells within the same tumor or from different tumors are highly heterogeneous. Furthermore, stromal and immune cells within tumor microenvironment interact with cancer cells to play important roles in how tumors progress and respond to different treatments. Recent advances in single cell technologies, especially massively parallel single cell sequencing, have made it possible to analyze cancer cells and cells in its tumor microenvironment in parallel with unprecedented high resolution. In this chapter, we will review recent developments in single cell sequencing technologies and their applications in cancer research. We will also explain how insights generated from single cell sequencing can be used to develop novel diagnostic and therapeutic approaches to conquer cancer.
- Open Access
Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer
Esophageal cancer (EC) is an aggressive form of cancer, including squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) as two predominant histological subtypes. Accumulating evidence supports the existence of cancer stem cells (CSCs) able to initiate and maintain EAC or ESCC. In this review, we aim to collect the current evidence on CSCs in esophageal cancer, including the biomarkers/characterization strategies of CSCs, heterogeneity of CSCs, and the key signaling pathways (Wnt/β-catenin, Notch, Hedgehog, YAP, JAK/STAT3) in modulating CSCs during esophageal cancer progression. Exploring the molecular mechanisms of therapy resistance in EC highlights DNA damage response (DDR), metabolic reprogramming, epithelial mesenchymal transition (EMT), and the role of the crosstalk of CSCs and their niche in the tumor progression. According to these molecular findings, potential therapeutic implications of targeting esophageal CSCs may provide novel strategies for the clinical management of esophageal cancer.
Open AccessLinking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer
Esophageal cancer (EC) is an aggressive form of cancer, including squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) as two predominant histological subtypes. Accumulating evidence supports the existence of cancer stem cells (CSCs) able to initiate and maintain EAC or ESCC. In this review, we aim to collect the current evidence on CSCs in esophageal cancer, including the biomarkers/characterization strategies of CSCs, heterogeneity of CSCs, and the key signaling pathways (Wnt/β-catenin, Notch, Hedgehog, YAP, JAK/STAT3) in modulating CSCs during esophageal cancer progression. Exploring the molecular mechanisms of therapy resistance in EC highlights DNA damage response (DDR), metabolic reprogramming, epithelial mesenchymal transition (EMT), and the role of the crosstalk of CSCs and their niche in the tumor progression. According to these molecular findings, potential therapeutic implications of targeting esophageal CSCs may provide novel strategies for the clinical management of esophageal cancer.